Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Enteropathy-associated T-cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
No randomised trial has been run in this disease. The regimen with the best results was compared against a historical group from the same region.
Many patients present as a surgical emergency in a malnourished state, so a substantial proportion are never well enough to receive the treatment that works best.
NCI PDQ states that a gluten-free diet prevents the lymphoma developing in coeliac disease and that people diagnosed with coeliac disease in childhood rarely develop it. That rests on observation; no trial has tested it, and many patients learn they have coeliac disease only when the lymphoma is found.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
The diagnosis is often made on bowel resected as an emergency for perforation or obstruction. Where there is time, it is made at endoscopy with biopsies of the small bowel. Coeliac disease is confirmed or newly diagnosed at the same time, and the rest of the family is offered testing. Staging uses the gastrointestinal system that counts depth and node involvement, and imaging of the whole abdomen matters because disease is often multifocal.
The International Consensus Classification lists type II refractory coeliac disease as a provisional entity; WHO-HAEM5 does not list it separately.
The revised fourth edition of the WHO classification separated the type that is not associated with coeliac disease and gave it its own name, monomorphic epitheliotropic intestinal T-cell lymphoma.
In the population-based series from northern England and Scotland, the 54 patients diagnosed between 1994 and 1998, of whom 35 had chemotherapy (mostly anthracycline-based) with or without surgery and 19 had surgery alone, had a median progression-free survival of 3.4 months and overall survival of 7.1 months. From 1998 the same group gave patients fit enough for it ifosfamide, etoposide and epirubicin alternating with methotrexate, followed by an autologous stem cell transplant; in 26 patients treated that way, five-year progression-free survival was 52 per cent and overall survival 60 per cent. That is a comparison against a historical group from the same region rather than a randomised trial; a 2026 paper summarises the later prospective United Kingdom phase 2 study of the approach as showing more modest outcomes, with one-year survival of 45 per cent. NCI PDQ calls the evidence for transplant consolidation anecdotal. A clinical trial is a reasonable first choice.
Among 54 patients identified in northern England and Scotland, incidence was 0.14 per 100,000 a year and, with chemotherapy in 35 and surgery alone in 19, median progression-free survival was 3.4 months and overall survival 7.1 months; 26 patients given ifosfamide, etoposide and epirubicin with methotrexate followed by autologous transplant had five-year progression-free survival of 52 per cent and overall survival of 60 per cent.